Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) have been given an average rating of “Buy” by the seven research firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $37.80.
Several equities research analysts have recently weighed in on YMAB shares. HC Wainwright decreased their price target on Y-mAbs Therapeutics from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Monday, February 28th. Zacks Investment Research raised Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 21st. Guggenheim started coverage on Y-mAbs Therapeutics in a research note on Thursday, February 3rd. They issued a “buy” rating and a $22.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price target on Y-mAbs Therapeutics from $30.00 to $27.00 and set a “neutral” rating for the company in a research note on Monday, January 3rd.
Shares of YMAB opened at $12.82 on Friday. Y-mAbs Therapeutics has a 12-month low of $6.50 and a 12-month high of $39.82. The business has a 50-day simple moving average of $10.17 and a two-hundred day simple moving average of $15.93. The stock has a market cap of $560.36 million, a PE ratio of -9.94 and a beta of 1.36.
In other Y-mAbs Therapeutics news, insider Thomas Gad sold 8,000 shares of the stock in a transaction that occurred on Tuesday, January 18th. The stock was sold at an average price of $11.54, for a total value of $92,320.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Bo Kruse sold 4,000 shares of the stock in a transaction that occurred on Monday, January 24th. The stock was sold at an average price of $9.84, for a total value of $39,360.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 419,189 shares of company stock worth $3,905,095. Corporate insiders own 27.28% of the company’s stock.
Several hedge funds have recently bought and sold shares of YMAB. Point72 Hong Kong Ltd bought a new position in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $28,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $49,000. Advisor Group Holdings Inc. bought a new stake in Y-mAbs Therapeutics during the fourth quarter worth $67,000. BNP Paribas Arbitrage SA lifted its holdings in Y-mAbs Therapeutics by 41.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 9,100 shares of the company’s stock worth $148,000 after acquiring an additional 2,651 shares during the period. Finally, Millennium Management LLC bought a new stake in Y-mAbs Therapeutics during the fourth quarter worth $204,000. Institutional investors own 67.21% of the company’s stock.
Y-mAbs Therapeutics Company Profile (Get Rating)
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
- Get a free copy of the StockNews.com research report on Y-mAbs Therapeutics (YMAB)
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.